Despite its presumed intuitive appeal, the concept of applying pharmacogenomics to predict drug response remains largely unproven, and the handful of companies trying for a foothold in this market face challenges on several fronts: finding drug companies who've bought into the concept and are willing to collaborate, negotiating deals without the leverage of issued patents linking SNPs and haplotypes to drug response, and convincing investors both that the technology won't be commoditized, and that pharmaceutical firms won't bring it in-house and leave them in the cold. Variagenics is assuming that drug companies with whom it partners will use data from clinical trials that incorporate pharmacogenomic assays to obtain a label linking the sale of the drug and the use of the tests, which Variagenics will supply or license. As it seeks partners, Variagenics is also raising its visibility by collaborating with CROs and offering expertise and services to those drug companies and biotechs who have yet to devote resources to in-house pharmacogenomics programs but who want a taste of the technology.
by Mark L. Ratner
Despite its presumed intuitive appeal, the concept of applying pharmacogenomics to predict drug response remains largely unproven. The handful of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.